This is a four-center open-label study designed to determine activity of Velcade in
Myelodysplastic Syndrome (MDS) patients. A total of 28 subjects will be enrolled. The
patients will be registered to GIMEMA Data Center before therapy starts and after inclusion
criteria verification.